$ADXN News

Last published 2h ago

2h agoADXNAddex Spin-out Neurosterix Closes $105 Million Series B FinancingGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR
1w agoADXNADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARESGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
1mo agoADXNAddex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for SchizophreniaGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
2mo agoADXNADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027GlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
4mo agoADXNAddex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and WakefulnessGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 8, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
4mo agoADXNAddex Shareholders Approve All Resolutions at Annual General MeetingGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
4mo agoADXNAddex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
4mo agoADXNAddex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026GlobeNewswireGeneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological
5mo agoADXNAddex Convenes Annual General Meeting 2026GlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
6mo agoADXNAddex Reports Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireGABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued to reposition dipraglurant mGlu5 NAM for brain injury recoveryEntered option
6mo agoADXNAddex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough ModelGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
6mo agoADXNAddex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026GlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
6mo agoADXNAddex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough ModelGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
9mo agoADXNAddex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder TreatmentGlobeNewswireData published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on
10mo agoADXNAddex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for SchizophreniaGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
11mo agoADXNAddex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.GlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
11mo agoADXNAddex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
11mo agoADXNAddex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025GlobeNewswireGeneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for
1y agoADXNAddex Increases Issued Share Capital to Create Treasury SharesGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
1y agoADXNAddex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate UpdateGlobeNewswireCash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB
1y agoADXNAddex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025GlobeNewswireGeneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological
1y agoADXNAddex Appoints Bank of New York Mellon as Depositary BankGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
1y agoADXNAddex Shareholders Approve All Resolutions at Annual General MeetingGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and
1y agoADXNAddex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate UpdateGlobeNewswireStrong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior
1y agoADXNAddex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025GlobeNewswireGeneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological
1y agoADXNAddex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical ModelsGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
1y agoADXNAddex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough ConferenceGlobeNewswireGeneva, Switzerland, June 5, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological
1y agoADXNAddex Convenes Annual General Meeting 2025GlobeNewswireGeneva, Switzerland, June 3, 2025 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders,
1y agoADXNAddex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling StudiesGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
1y agoADXNAddex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury RecoveryGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
1y agoADXNAddex Reports Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireLaunched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolioIndivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance
1y agoADXNAddex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025GlobeNewswireGeneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological
1y agoADXNAddex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149GlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
1y agoADXNAddex to Present at the 2025 Swiss Equities Baader ConferenceGlobeNewswireGeneva, Switzerland, January 8, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological
1y agoADXNAddex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoADXNAddex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireIndivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex
2y agoADXNAddex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024GlobeNewswireNine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company
2y agoADXNAddex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoADXNAddex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate UpdateGlobeNewswireLaunched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophreniaIndivior selected GABA B PAM drug candidate for development in substance use disordersAddex selected independent GABAB
2y agoADXNAddex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net ProfitGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
2y agoADXNAddex to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireGeneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological
2y agoADXNAddex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research CollaborationGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
2y agoADXNAddex's Partner Discontinues ADX71149 development in EpilepsyGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
2y agoADXNAddex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)GlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
2y agoADXNAddex To Present at the Thirteenth London International Cough Symposium (13th LICS)GlobeNewswireGeneva, Switzerland, July 12, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological
2y agoADXNAddex Shareholders Approve All Resolutions at Annual General MeetingGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and
2y agoADXNAddex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoADXNAddex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate UpdateGlobeNewswire● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics
2y agoADXNAddex Convenes Annual General Meeting 2024GlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
2y agoADXNAddex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024GlobeNewswireGeneva, Switzerland, May 31, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders,